Calendar of Events

The second session will introduce the different Specialty Interest Groups at SOT and give examples of their resources available to members. We will highlight programs within SOT that aim to promote diversity and bring additional support for members of groups underrepresented in the sciences. Three speakers from Toxicologists of African Origin (TAO), Hispanic Organization of Toxicologists (HOT), and the Graduate Student Leadership Committee (GSLC) will explore how SOT has been a resource to them during their professional development and while creating a network of fellow toxicologists. The session will showcase various opportunities SOT offers for professional development and advancing diversity.

Alexandra Noel
Assistant Professor
Louisiana State University

Registration is required.

Host: Inhalation and Respiratory Specialty Section (IRSS)
Date and Time: Friday, December 13, 2019, 12:00 Noon–1:00 PM (ET)

Registration is Required

Wildfires are increasing in size and severity, with severe impacts on air quality and respiratory health. Wildfire smoke is associated with increased mortality and respiratory morbidity, including increased medication usage, emergency department visits, and hospitalizations. However, the clinical impacts and molecular mechanisms are not well characterized. Therefore, defining the respiratory toxicities of wildfire exposure is critical. This webinar will introduce the epidemiological data regarding community exposures during wildfires (presented by Dr. Mary Rice), and then define the toxicological mechanisms by which wildfire smoke exposure can impact pulmonary health (presented by Dr. M. Ian Gilmour). The webinar will cover human, mouse, and in vitro studies to date.

Co-chairs: Sarah Carratt and Pam Lein

Endorsement: Education and Career Development Committee (ECDC), Graduate Student Leadership Committee (GSLC), Women in Toxicology (WIT)

Karilyn Sant, Ph.D.
San Diego State University

Registration is required.

Ivan Rusyn, MD, PhD
Department of Veterinary Integrative Biosciences
College of Veterinary Medicine & Biomedical Sciences
Texas A&M University
College Station, TX

Attendee link: https://aim-hq.webex.com/aim-hq/onstage/g.php?MTID=ef8eebb26404deea9d64a23c5c4fb9402

Teleconference information

Event Information: IVAMSS Webinar: 2019 Student Research Award Winners

Date and time: Thursday, January 9, 2020 11:00 am
Eastern Standard Time (New York, GMT-05:00)

Duration: 1 hour

Description:
Piecing Together the Puzzle: Identifying the Role Oxidative Stress and the Alveolar Epithelium Play in Air Pollution Induced Cardiovascular Disease
Presented by Eva Vitucci

An estimated 3.5-million people die every year from air pollution-induced cardiovascular disease (API-CVD); however, while in vivo data has demonstrated associations between induced CVD and systemic oxidative stress, the causative molecular mechanisms driving API-CVD are still poorly understood. To identify the mechanisms of action driving API-CVD, we developed a unique, tri-culture in vitro model that represents the interface of the alveolar epithelial barrier (AEB) and the cardiovascular system. We hypothesized that air pollutant exposure of human alveolar-like epithelial cells (H441) would induce oxidative stress in adjacent, but physically separated, human pulmonary vasculature cells leading to vascular damage. To test this hypothesis, we exposed confluent, electrically-resistant, and small molecular-impermeable monolayers of H441 cells, grown on the apical surface of Transwell permeable membranes, to the ubiquitous air pollutant, diesel exhaust particulates (DEP), with human lung fibroblasts on the underside of the Transwell membrane and human microvascular lung endothelial cells (HULEC) in the basal compartment. Upon DEP exposure, we identified a variety of oxidative stress responsive genes induced in the directly exposed H441 cells and in the indirectly exposed HULEC, including heme oxygenase 1 (HMOX-1) and NAD(P)H dehydrogenase [quinone] 1 (NQO1). These changes in gene expression occurred despite a lack of change in trans-epithelial electrical resistance (TEER) and small molecule (20kDa fluorescein isothiocyanate (FITC)-dextran) permeability, suggesting that they result from the release of epithelial/fibroblast-derived mediators and/or compounds/metabolites that traverse the epithelial cells. Collectively, these data suggest that induction of oxidative stress in nearby endothelial cells may be mediated by epithelial cells and may be an important mechanism of API-CVD. We conclude that we have developed a relevant, in vivo-like, in vitro model of the AEB-cardiovascular system interface which can be used to identify the elusive molecular mechanisms driving API-CVD. Ultimately, data derived from this model can be used to identify therapeutic targets, biomarkers of both susceptibility and exposure effects, and can encourage the continued development of similar biomimetic models resulting in a reduction of non-essential animal testing.

Functional Comparison of HepaRG Cells and Primary Human Hepatocytes in Monolayer and Spheroid Culture as Repeated Exposure Models for Hepatotoxicity
Presented by Jinpeng Li

Reliable and effective prediction of hepatotoxicity resulting from repeated exposure to chemicals is of critical importance for the safety assessment of chemicals. However, in vitro long-term repeated exposure studies are difficult to conduct using conventional hepatocyte monolayer cultures due to their rapid de-differentiation and subsequent loss of hepatocyte function. Towards this end, significant advancements have been made to maintain hepatic physiology for an extended period of time by culturing hepatocytes in vitro as three-dimensional (3D) spheroidal aggregates. Here, we compared two promising model systems, HepaRG and primary human hepatocytes (PHH), in both 3D spheroid and traditional 2D monolayer cultures to evaluate their potential as predictive models for assessment of hepatotoxicity. When compared to 2D cultures, cells in spheroid culture maintained higher levels of viability for a longer duration. Likewise, functional characterization revealed higher levels of xenobiotic metabolic activity (CYP1A2, CYP2B6 and CYP3A4) and urea production in spheroid vs 2D cultures. In addition, spheroid cultures showed increased sensitivity to a set of hepatotoxic compounds (ibuprofen, ibufenac, acetaminophen and aflatoxin B1) after repeated exposure (e.g., EC50 of aflatoxin B1 was reduced by 84% in PHH and 68% in HepaRG spheroids as compared to respective 2D cultures), and the sensitivity was further elevated by extended exposure duration (e.g., EC50 of aflatoxin B1 was further reduced by 25% in PHH and 73% in HepaRG spheroids when treated for an additional week). Moreover, HepaRG spheroids exhibited similar sensitivity as PHH spheroids especially in extended exposure, suggesting that HepaRG could be a reliable surrogate for PHH and serve as a repeated exposure model to predict hepatotoxicity.

Registration is required.

Event Information: DTSS Webinar: Best of the Dermal Toxicology Specialty Section: 2019 Scientific Award Winners

Date and time: Monday, January 13, 2020 1:00 pm
Eastern Standard Time (New York, GMT-05:00)

Duration: 2 hours

Description:
The Dermal Toxicology Specialty Section presents annual awards for scientific studies related to toxicity of the skin. In 2019, three winners were chosen from the members of this section based on their scientific accomplishments. The objective of this webinar is for the winners to showcase their award-winning research.

The first presentation will be by Dr. Yoke-Chen Chang who, along with her co-authors, was awarded the DTSS Paper of the Year Award. This work investigated the expression of cytokines and chemokines in mouse skin treated with the chemical warfare agent sulfur mustard. They found that inflammatory cell-derived mediators contribute to the pathogenesis of sulfur mustard induced skin damage.

The second presentation will be by Dr. Xue (Lucia) Liu. She and her collaborators developed a novel bio-printed vascularized full thickness skin equivalent and a reconstructed human epidermis in a multi-well plate format. The purpose for the development of these 3-dimensional tissue models is for high-throughput drug screening. The tissues developed in this study offer an in vitro approach for understanding the pharmacologic and toxicologic mechanism of action of drugs applied to the skin.

The third presentation will be by Ms. Sarah Dickinson. Recent evidence suggests that sunscreens, used to protect the skin from damaging ultraviolet radiation from the sun, have off-target effects. The results from this study suggest that the sunscreen octinoxate modulates AhR activity via inhibition of cytochrome P450 1A1. Alteration of AhR activity and signaling has many potential implications on the functions of skin.

Speakers
Yoke-Chen Chang, PhD
Rutgers University

Xue (Lucia) Liu, PhD
NIH

Sarah Dickinson
University of Rochester

Registration is required

Event Information: FSSS Webinar: Microbiome: The Missing Piece in the Diet/Health Puzzle

Date and time: Wednesday, January 15, 2020 11:00 am
Eastern Standard Time (New York, GMT-05:00)

Duration: 1 hour 30 minutes

Description: Appropriate mutualistic and commensal host/microbiome interactions provide beneficial effects to one or both species, while adverse host/microbiome interactions contribute to disease. Two speakers will describe the effects of diet and foodborne agents on gut microbiota and the effects of gut dysbiosis on health.

Speakers:

Tiffany Weir, PhD

The gut microbiota has emerged as an important regulator of human health. Imbalances in the gut microbiota, referred to as dysbiosis, have been associated with numerous disease both within the intestines as well as in peripheral tissues in organs. Gut dysbiosis is often characterized by reduced microbial diversity and loss of functionality and can lead to increased intestinal inflammation and loss of gut barrier function. While numerous factors can impact the intestinal microbiota, including age, stress, medications, pollutants, and exercise- diet has the greatest potential to modify the microbiota. Our laboratory studies how diet-induced alterations to the microbiota can prevent or increase the risk of developing cardiometabolic diseases. In this webinar, we will explore the role the microbiota plays in disease development and examine some of the underlying mechanism and how external factors shape the microbiota with a focus on dietary components.

Sangeeta Khare, Ph.D.

This talk will provide approaches for the risk assessment of intentional and unintentional use of antimicrobials (metal-based nanomaterial) and antimicrobial residues (antibiotics). Usually these products are used as health supplements or are present as drug residues in consumer products. Interactions of these products with the gastrointestinal tract might have an adverse effect on the commensal microbiota, impact antimicrobial resistance and alter the host immune responses and intestinal permeability.

Registration is required to join this event.

Event Information: MDCPSS Webinar: Impact of 2017/745 EU Medical Device Regulation (MDR) on Biological Evaluation of Medical Devices

Date and time: Thursday, January 16, 2020 11:00 am Eastern Standard Time (New York, GMT-05:00)

Duration: 1 hour

Description:
This webinar will focus on the impact of the 2017/745 EU Medical Device Regulation (MDR) on biological evaluation of medical devices. The webinar will compare relevant MDR General Safety and Performance Requirements (GSPR) with the Medical Devices Directive (MDD) Essential Requirements; compare MDR GSPR with ISO 10993 and ISO 14971; and discuss the impact of changes in ISO 10993-1:2018 and other ISO standards. A generous Q&A session is planned to accommodate conversation with the speaker—Chairman of ISO/TC 194 Biological Evaluation and Director of Regulatory Consultancy and Quality Assurance at an EU Authorized Representative, regulatory consultancy, and CRO.

Speakers
Jeremy Tinkler
Director of Regulatory Consultancy and Quality Assurance
MedPass International SAS

Rachel Hardy
Senior Strategy Consultant
MedPass International SAS

Registration is required.

- Increased perspective from CROs
- Representation from regulatory authorities
- Functional implementation of TMF systems
- Risk-based monitoring and processes
- Exploring functional areas and their teams
- Innovations and advancements in technology
- Collaboration with clinical sites

Venue Details: Sheraton Orlando Lake Buena Vista Resort, 12205 South Apopka Vineland Road, Orlando, 32836, United States

Date and Time: On Tuesday January 21, 2020 at 9:00 am ends Thursday January 23, 2020 at 5:00 pm

Top Five Reasons to Attend:
*To assess REMS efficacy with proven methods from industry professionals
*Complying with regulations pertaining to standardization and evaluation
*Collaborate with industry leaders on innovative approaches for REMS design, implementation, and solutions
*Increase knowledge and awareness of upcoming REMS technologies, innovation and regulatory changes
*Discussing the challenges of recent FDA guidelines impacting REMS

REMS
Risk Management
Pharmacovigilance/Surveillance
Quality Assurance
Drug/Product Safety
Clinical Risk Management
Lifecycle Management
Regulatory Affairs/Legal/Compliance
Clinical Affairs
Clinical Data Management
Clinical Operations
Clinical Risk Management Compliance
Epidemiology/Pharmacoepidemiology
Marketing

Registration is required.

Four years in the drug development world isn’t long, and the progress made in continuous processing has been an extraordinary. Thanks to the encouragement of the FDA and maturing technology; both pharma and biotech are starting to adopt continuous manufacturing (CM) in a commercial setting.

At the 4th Annual CCP Summit we will continue to explore scientific and technology advancements that can help eliminate bottlenecks, and more importantly, will address the quality, upfront investment and business rationale behind the ‘switch’.

Event Information: IVAM-SS Webinar: NAMs Case Study : Industry/Government Partnerships

Date and time: Wednesday, January 29, 2020 11:00 am
Eastern Standard Time (New York, GMT-05:00)

Duration: 1.5 hour

Description:
This webinar will use a case study to discuss the process of leveraging industry/regulatory partnerships to work more efficiently and effectively as we forge ahead in the NAMs space. We will have two speakers, Monique Perron from US EPA, and Doug Wolf from Syngenta. The speakers will discuss the processes they took as they worked through an alternative approach to the 90-day inhalation animal study, highlighting key watch-outs and suggestions from their experience.

Presenters
Monique Perron, Sc.D
Acting Branch Chief, Risk Assessment Branch IV
US EPA, OPP, HED

Douglas C. Wolf, DVM, PhD, FIATP, ATS
Senior Syngenta Fellow, Product Safety

Registration is required

Donna Voorhees, PhD
Director of Energy Research
Health Effects Institute (HEI)
Boston, MA

Onshore development of oil and natural gas from unconventional resources (unconventional oil and gas development, abbreviated in this presentation as “UOGD”) has expanded rapidly in the United States during the last decade and, along with it, concern about its potential health effects. While UOGD shares many attributes of conventional oil and gas development that has been around since the 1800s, it is occurring in locations and at a scale not always familiar to those living nearby. This presentation will summarize methodologic challenges and opportunities in understanding the potential for health effects, especially through risk-based analyses.

Beginning in 2012, academic scientists and public health authorities published human health risk assessments and risk-based screening assessments that combined information about potential UOGD-related chemical concentrations with relevant toxicity information to predict risk to communities in Colorado, North Dakota, Pennsylvania and the broader Marcellus region, Texas, and Wyoming. Nearly all assessments quantified risk to community members associated with potential exposure to UOGD-related chemicals in air, but several assessed risks involving water. Assessments varied in their complexity, from screening-level comparisons of chemical concentrations, to health-based benchmarks, to more involved assessments measuring potential exposure specific to a population, including control for baseline, or background, conditions. Conclusions differed among the risk assessments and were subject to important sources of uncertainty about exposure and toxicity and the judgments made by investigators to address them. The body of work also was limited in its relevance to operations, regions, and populations beyond those that were the subject of each assessment. Future investigators must grapple with the extensive temporal and spatial variability in potential exposure as a function of numerous factors (e.g., differences in regulations, environmental conditions, and practices among UOGD operators), the uncertainties about potential exposure (e.g., when and where will operations happen, the identity of chemicals being used, the efficacy of noise mitigation), and the lack of toxicity information for some chemicals associated with UOGD operations.

Teleconference information

It takes immense pleasure to invite you to attend 4th International Conference on Chronic Diseases (Chronic Diseases 2020) scheduled to be held in Paris, France during February 17-18, 2020.
Chronic Diseases 2020 is a global event focusing on the immense knowledge and major advances in the rapidly emerging fields of chronic diseases by attracting experts and professionals across the universe.

Visit: https://chronicdiseases.cmesociety.com/

Oxford Global is proud to present for the 15th year our flagship Biomarkers Series UK, 18 – 20 February 2020, Manchester, UK. This year promises to be the most exciting Biomarkers Series to date, with a host of new features alongside the popular programme to ensure you gain vital updates on the latest biomarker initiatives and technologies.

Featuring the following interactive streams:

New for 2020, we are pleased to announce the following features:

- The Inaugural Genomic Markers Congress: Two dedicated streams on the integration of genomic markers into drug development to enable precision medicine
- A pre-event focus day: Deep-dive sessions in the morning to provide insights into key therapeutic areas from leading experts and end-user workshops in the afternoon to showcase key platforms to incorporate in your workflow. Spaces are limited, so sign-up early to avoid disappointment
- Our Day 1 workshop on Biomarker Qualification: Technical Validation and Regulatory Aspects
- Our Day 2 workshops on Data Analysis and Bioinformatics and Genomic Biobanking to Facilitate Precision Medicine

On Tuesday February 18, 2020 at 7:00 am (ends Thursday February 20, 2020 at 7:00 pm)

Over the past few years, 3D Cell Culture has gained momentum within the pharmaceutical industry due to the benefits that this model offers for in vitro applications patient-derived tissues, drug discovery, predictivity and validation, and safety and toxicity.

Bioprinting has become increasingly efficient and accurate in building in vitro tissue models with the potential to provide pathologically relevant responses and model human disease mechanisms. Bio-printed structures yield phenotypic endpoints that are comparable with clinical studies and can provide a realistic prediction of clinical efficacy. The use of bioprinting is growing in big pharma companies as an alternative to organ-on-a-chip systems.

WHO SHOULD ATTEND?
Biotech / Pharma Companies - Team Leader, Junior Principle investigator, Cell and Molecular Scientist, Chief Scientific Officer, Deputy Director, Manager, Founder, CEO, Head, Director, Programme Manager, Lab Head, Toxicologist
Academia Professor - Cell Technology, Stem Cell Sciences, Biochemistry, Protein Technology and Tissue Engineering
Solution Providers – Manager, Head of, CEO, Director, Founder, Account Manager, President, CSO, Executive, Managing Director

Registration is required.

For Registration: http://stemcell.alliedacademies.com/registration

Contact Details:

Leon Bezos,
Program Director,
Stem Cell 2020,
E: stemcellcongress@geneconferences.com
Tel: (+44) 2037691755
What's App: (+44) 1403582077

7 Conference Session Themes:
- Novel Engineering and Discovery Strategies
- ADCs/Antibody-Drug Conjugates
- Bispecific Antibodies and Multi-Functional Biologics
- Immuno-Oncology
- Preclinical and Clinical Case Studies
- Delivery Strategies and Crossing/Penetrating Biological Barriers
- Engineering Strategies for TCR and CAR T Cell Therapies

This year's summit will take a deeper look at:

Walk away with a blueprint for more accurate, more efficient and more effective RandD processes.

Uniting the leading minds from large pharma, biotech and academia, this summit will help you advance novel target site discovery, improve drug-like properties and accelerate the translation of potent and mutation-specific RAS targeted therapeutic strategies into human clinical trials. With numerous approaches emerging that demonstrate genuinely viable efficacy in targeting the RAS family of proteins, join the RAS- Targeted Drug Discovery Summit Europe to gain first-hand insights on the challenges and strategies to robustly translate promising anti-RAS therapies into the clinic.

Target Audience:

• Academic, industry and government researchers engaged in developing therapeutic approaches and medical countermeasures (MCMs) against ocular pathologies resulting from exposure to chemical toxicants
• Government stakeholders and funding agencies

Objectives of the Scientific Meeting:

• Development of MCMs that mitigate acute and chronic corneal manifestations in response to ocular toxicants relies on the development of well-characterized experimental models with defined pathophysiology that allow for effective bridging to humans. Such models are also essential to demonstrate therapeutic efficacy.
• This meeting will bring together subject matter experts from the civilian and military research communities to discuss the current state of the field, including potential therapeutic approaches and available models.
• Attendees of the workshop will contribute to our understanding of pathologies and models available for studying toxic ocular injuries and their utility in the research and development of therapeutics. Most importantly, the workshop will address current knowledge gaps to identify possible refinements or new directions to advance MCM development.

Session Topics:

• Acute and Chronic Responses to Corneal Toxicity
• Mechanistic Basis of Corneal Pathophysiologies and Wound Healing
• Therapeutically Accessible Models of Corneal Toxic Injury
• Therapeutic Approaches to Mitigate Corneal Pathophysiologies
• Current Research/Development Perspectives and Resources for Researchers
• Meeting Wrap Up

Organizers:

• National Eye Institute (HHS/NIH/NEI)
• U.S. Army Medical Research Institute for Chemical Defense (DoD/USAMRICD)
• National Institute of Allergy and Infectious Diseases (HHS/NIH/NIAID)

Opportunities for travel awards, oral and/or poster presentations are available - see

Invitation

Dear Colleagues,
On behalf of Beni- Suef University, Egypt, we are delighted to invite all scientists from academia and industry and representatives of national and international agencies, to attend the International conference: Environmental Pollution Risks in Developing Countries (EPRDC 2020)
Under the Patronage of:
Prof. khaled Abdul Ghaffar –Minister of Higher Education and Scientific Research
Prof. Mansour Hasan- President , Beni - Suef University
Prof. Badr Nabeh, Vice President, Beni Suef University
Prof. Khaled Abbas Helmy Abdou General Secretary, Beni Suef University

Conference theme:

Environmental pollution risks in developing countries (EPRDC 2020)
?????? ?????? ??????? ?? ??????? ???????
3 – 4 MARCH, 2020 - Beni Suef University, Egypt

Objectives:
1. Exchange the state of the art on climate change and environmental sciences.

2. Gathering scientific information and experiences in order to identify the common and urgent environmental issues in developing countries.

4. Exchange the knowledge related to the new green technology aspects.

Topics:
1- Environmental pollution.

3-Innovative technologies of environmental monitoring.
4-water quality and wastewater management .
5- Environmental pollution and food safety.
6- Renewable energy.
7- Waste management and sustainability.
8- Green chemistry
9- Climate changes and environmental hazards.
The organizers of the International Symposium on environmental pollution risks in developing countries (EPRDC 2020) promise to prepare a balanced programme including oral presentations workshops, , interactive seminars and nice social events.
We are looking forward to meeting you again in Egypt

• Registration and payment information:
Fee:
Participant
category Early registration Late registration
Egyptians
(LE) Non Egyptians
($) Egyptians
(LE) Non Egyptians
($)
Non-Bsu Participants 300 300 350 350
BSU- members 150 150 200 200
Student 100 100 150 150

- Payment by cash to the Beni- Suef University (9/450/87972/7).
- Deadlines
1-Early registration:31 December 2019.
2- submission of abstracts and late registration : 15 February 2020

Guidelines for submission
Poster submission :
Please ensure your poster does not exceed the poster board dimensions; 75 cm wide x 100 cm high
Oral submission:
Microsoft power point or PDF
Abstract submission
Font size 12, Normal, Times New Roman, 1.5 space
• Official languages: English- Arabic
Contact us:

Conference Secretary:
- RAGAA AZZAT : 01002679489
- DALIA ELFOULY: 01068813441
- Amro Mohamed : 01000086960

Get in touch :
Web site : www.eprdc2020. bsu .edu.eg
Face book: https://www.facebook.com/EPRDC2020
EMAIL : eprdc2020@bsu.edu.eg

Travel Grants for Trainees available

Early bird registration deadline: December 13, 2019

Call for Poster Deadline: January 31, 2020

Keynote Addresses

Linda Birnbaum PhD, NIEHS director (retired)

Dean P Jones PhD, Emory University

visit

With scarce treatment options leaving inborn errors of metabolism a devastating, unfilled and unmet medical need, the opportunity for biopharma to do better and aggressively tap into a lucrative and life changing market of gene modalities is growing. For the first time, the Inborn Errors of Metabolism Drug Development summit will look to examine how the experience within existing pharmacology for rare metabolic diseases can be leveraged with the drug development strategies of those pioneering gene modalities to improve efficacy, safety and commercial viability.

This is your comprehensive guide to define your drug development path for 2020. Don’t miss out on your chance to network with industry leaders and be a part of the only enriched industry forum focused on accelerating the development of better effective treatments for inborn errors of metabolism.

Obesity-2020 conference includes Plenary lectures, Keynote lectures and short courses by eminent personalities from around the world in addition to contributed papers both oral and poster presentations.

The theme of the Conference is “Science and education for action against HPV”. Through workshops, lectures, oral and poster sessions presenting the latest research results, the program will cover papillomavirus (PV)-related topics from basic science to global health impact. We will be paying special attention to HPV prevention and control in populations that are most vulnerable to HPV disease worldwide, including those in Low- and Middle-Income Countries.

Our overarching theme will be harnessing the power of innovation from HPV research to deliver global prevention and control of HPV-related disease.

See you at IPVC 2020!

As phage therapy offers an opportunity to tackle the ever-growing problem of antibiotic resistant infections, the 2nd Bacteriophage Therapy Summit returns to not only drive forward the translation of phage pharmacology into the clinic but also generate discussion around the direction that phage therapy is heading and how this can be commercialized and delivered into the hands of physicians and patients in need.

With a clear focus on overcoming the translational and development challenges of this re-emerging therapeutic class, join your peers to be part of the discussion to facilitate the translation of phage products into targeted, clinically successful therapeutics.

The 4th Annual Gene Therapy for Rare Disorders will focus exclusively on overcoming the late-stage commercial challenges drug developers face when delivering gene therapies to market.

Incorporating insights from 80+ industry-leading speakers, this conference will delve into the key regulatory, reimbursement, clinical and manufacturing hurdles that need to be overcome to realize the commercial potential of gene therapies.

This is your comprehensive guide to define your commercial path forward in 2020.

Join 2000+ pharma decision-makers and healthcare innovators to:

Why you need to attend:

-9 dedicated conference streams: Barcelona is huge – 2000+ people in total. Yet it’s also intimate, tailored just for you. You’ll spend most of the conference in one of 9 tracks with sessions that hit all your buttons.
- All stakeholders. All functions. 1 place: The most cross-functional pharma event in the world – executives from marketing, commercial, sales, market access, medical affairs, patient engagement, RWE, IT, clinical and more.
- More than just conference sessions: Sometimes, the best ideas don’t come from the stage. They come from those chance happenings when you joined a roundtable or went to a networking evening.

Venue Details: Centre de Convencions Internacional de Barcelona, 11-14 Plaça de Willy Brandt, Barcelona, 08019, Spain

Once again, the conference will bring together the leading microbiome companies working to successfully commercialize microbiome-based diagnostics, therapeutics, adjunct therapies and direct-to-consumer services and products across a range of therapeutic areas, from gut to skin and beyond. Expanding on this core focus year on year, we continue to offer informative, hands-on workshops, panels sponsored and directed by industry to focus on your concerns and tightly curated content that goes beyond the usual infomercials to provide tangible and useful insights to how your peers are addressing their commercial approach to the space.

Over 300 pharmaceutical scientists working across formulation, drug delivery and manufacturing science and technologies, representing global pharmaceutical organisations, leading biotech and internationally renowned academic institutions

PLUS interactive opportunities including:
- Roundtable discussions
- Panel discussions
- Pre-event podcasts and webinars

Co-located with the 3rd Annual Inhalation and Respiratory Drug Delivery USA Congress.

Go Social: Join our Formulation and Drug Delivery Network on LinkedIn, follow us on Twitter @FDDCongress and join the conversation at #FDDUK20

*2020 Live Webinar*

CHAIRED BY: Lynne Ensor,VP Technical, Parexel

Join industry experts to discuss and analyze the latest advances and challenges within the industry. Network with industry professionals, discuss the revision of Annex 1, explore data integrity considerations for conventional and rapid microbiology methods, analyze arising issues with environmental monitoring and gain insight into an industry perspective on automated endotoxin testing and process automation.

Post-Conference Workshop – May 1, 2020
The Use of Recombinant Chromogenic Assays as Alternate Methods for the Bacterial Endotoxins Test (BET)
Workshop Leader: Veronika Wills, Manager, Technical Services, Associates of Cape Cod

Prices:
Conference + 1 Workshop: USD 2498.00
Conference Only: USD 1999.00
Workshop Only: USD 499.00

Time: 8:30 am to 5:00 pm

The unique scientific program of the Congress will bring you the latest updates in the field of autoimmune diseases, presented by the world's leading experts, while at the same time providing an amazing stage for young upcoming talents to present their research to a first-rate audience.

Established by Professor Yehuda Shoenfeld, the congress constitutes a network of international leaders on immunology, rheumatology and related fields, all of whom contribute their unique and diverse knowledge to the "family of autoimmunity."

SLAS Europe 2020 provides a unique combination of education, access to innovative technologies and intelligent peer networking, delivering unmatched value for professionals and students looking to discover the latest life sciences technologies and how they can be applied to drive research objectives.

This year, the symposium will be held on the Penn State University campus in State College, PA from June 14-18, 2020. The sessions will showcase cutting edge research and highlight advancements in the study of AHR in terms of public and environmental health, toxicology, pharmacology and biology of development. The themes of the symposium will therefore address many systems / models of pathologies related to environmental toxicology.

Along with opportunities to network with colleagues from around the world and learn the latest scientific information, the Penn State campus and surrounding area offers many things to do and see. Central Pennsylvania is a beautiful part of the United States boasting scenic mountains, local culture, and a world class research institution. Come for the meeting, but make sure to take advantage of all the area has to offer.

To explore foremost research in pharmaceutical sciences and to discuss clinical, analytical and commercial issues in pharmacology, Pages Conferences is organizing Global Conferennce on Pharmaceutics and Pharmacology, which will be held during August 06-07,2020 in San Antonio. The conference offers a seamless view of the industry today while paving way for future research.

The conference aims to empower future generations in different fields of pharmaceutics to explore exciting research outcomes that lie in tune with the objectives and theme of this exciting event. It further helps you enhance your understanding of commercial, scientific and regulatory issues that affect strategic decision making in the pharmacology sector.

Sessions Link: https://pagesconferences.com/pharmacology-pharmaceuticsconference/call-for-abstracts.php

Contact us:

Julie Andrieo
gcpp-2020@pagesconferences.com

To provide critical information and knowledge based on latest research in toxicology, Scientific Federation is organizing the Global Conference on Toxicology which is scheduled to be held during August 06-07,2020, in San Antonio, USA. The aim of this conference is to share critical toxicology information to protect public health.

For more information:

Satya | Program Manager
Toxicology-2020
gct-2020@pagesconferences.com

Every year we see innovation and breakthroughs at every level of drug development.

Covering both small molecules and biologics, you'll find new technologies, concepts and case studies in areas such as...